Noninvasive detection kit for susceptibility gene of bladder cancer

TL;DR: In this paper, a non-invasive detection kit for detecting a susceptibility gene of bladder cancer was provided, which comprises a specific primer and a DNA sequencing primer for detecting whether a GSTM1 (Glutathiones Tansferase M1) gene is null/present or not, the single nucleotide polymorphism of a G252A locus of a TNF (Tumor Necrosis Factor)-beta gene, a PCR (Polymerase Chain Reaction) reaction assembly, PCR product purification assembly, and the like.

Abstract: The invention provides a noninvasive detection kit for detecting a susceptibility gene of bladder cancer. The noninvasive detection kit comprises a specific primer and a DNA (Deoxyribose Nucleic Acid) sequencing primer for detecting whether a GSTM1 (Glutathiones Tansferase M1) gene is null/present or not , the single nucleotide polymorphism of a G252A locus of a TNF (Tumor Necrosis Factor)-beta gene, a PCR (Polymerase Chain Reaction) reaction assembly, a PCR product purification assembly, a DNA sequencing assembly and the like. According to the kit disclosed by the invention, the risk level of bladder cancer disease of a subject is assessed by detecting genotypes of two single nucleotide polymorphism locuses which are closely related with the bladder cancer and finally, the subject is guided to specifically prevent the bladder cancer from the gene level according to the gene detection result of each subject and the disease probability of the bladder cancer is reduced. According to the sampling method disclosed by the invention, oral mucosa cells are used as samples, no pains or invasion occurs and the crossed infection is avoided. The sequencing detection result is accurate and is reliable; imported special instruments with high price can be omitted; and the method is easy for popularization and generalization.